# A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants

> **NCT06615570** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 30 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-973
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06615570
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-30
- **Primary completion:** 2025-07-21
- **Final completion:** 2025-07-21
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615570, "A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06615570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*